Key result
Direct oral anticoagulants are preferred in chronic kidney disease stages 1-4, while apixaban and rivaroxaban demonstrate comparable efficacy to warfarin in end-stage renal disease.
Why the study?
Atrial fibrillation and chronic kidney disease frequently coexist, increasing thromboembolic and bleeding risks.
What are the optimal anticoagulation strategies for patients with atrial fibrillation and chronic kidney disease?
What are the optimal anticoagulation strategies for patients with atrial fibrillation and chronic kidney disease?
This review highlights that direct oral anticoagulants are preferred in mild-to-moderate CKD, while apixaban and rivaroxaban offer comparable efficacy to warfarin in end-stage renal disease.
Atrial fibrillation and chronic kidney disease (CKD) frequently coexist, increasing thromboembolic and bleeding risks. This is a narrative review of pathophysiology and clinical evidence for anticoagulation strategies in CKD patients. Direct oral anticoagulants are preferred in CKD stages 1-4. Recent data suggest that the efficacy of apixaban and rivaroxaban is comparable to that of warfarin in end-stage renal disease. In advanced CKD, anticoagulation should be tailored with close monitoring.
No takes yet. Share an insight, caveat, or question.
L et al. (2026) studied this question. Direct oral anticoagulants are preferred in chronic kidney disease stages 1-4, while apixaban and rivaroxaban demonstrate comparable efficacy to warfarin in end-stage renal disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: